ASPENBeiGeneEHAESMONSCLCPD-1Waldenström

Biomarker identification in relapsed/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma treated with Zanubrutinib

 Volver  Ver
Biomarker identification in relapsed/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma treated with Zanubrutinib
 POSTER   06/2020
 Ver

Para obtener más información sobre esta publicación, por favor envíe una solicitud de información médica.

Rating

Rate this publication

Publicaciones relacionadas

EHA 2020 & Library: selected abstracts on BeiGene products
EHA 2020 & Library: selected abstracts on BeiGene products
EHA25 - Virtual Satellite Symposium
EHA25 - Virtual Satellite Symposium
Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase 2, single-arm, multicenter, study
Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase 2, single-arm, multicenter, study
 Volver